Krischan J Hudson

2.1k citations

17 papers · 698 indexed · h-index 11

Co-authors: William Spreen David A. Margolis Susan L. Ford Britt Stancil Kimberly Y. Smith Sandy Griffith Parul Patel Miranda Murray
Topics: HIV/AIDS drug development and treatment (11 papers)HIV/AIDS Research and Interventions (10 papers)HIV Research and Treatment (9 papers)
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: SHILAP Revista de lepidopterologíaCHEST Journal The Lancet Infectious Diseases
Partner nations: United States United Kingdom Belgium

In The Last Decade

Krischan J Hudson

17 papers receiving 686 citations

Peers

Countries citing papers authored by Krischan J Hudson

Since Specialization

Citations

This map shows the geographic impact of Krischan J Hudson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krischan J Hudson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krischan J Hudson more than expected).

Fields of papers citing papers by Krischan J Hudson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krischan J Hudson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krischan J Hudson. The network helps show where Krischan J Hudson may publish in the future.

Co-authorship network of co-authors of Krischan J Hudson

This figure shows the co-authorship network connecting the top 25 collaborators of Krischan J Hudson. A scholar is included among the top collaborators of Krischan J Hudson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krischan J Hudson. Krischan J Hudson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis 2024 ·European Respiratory Review ·Elizabeth R. Volkmann,Christopher P. Denton,Martin Kolb,(unknown),Claire Emson,Krischan J Hudson,(unknown),Oliver Distler,(unknown),Dinesh Khanna	6
2	PHARMACOKINECTS STUDY TO EVALUATE DRUG-DRUG INTERACTIONS (DDI) BETWEEN HZN-825 AND PIRFENIDONE/NINTEDANIB 2023 ·CHEST Journal ·Yang Song,Krischan J Hudson,(unknown),Wei Chen,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	3
3	Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials 2021 ·BMC Health Services Research ·Andrea Mantsios,Miranda Murray,Tahilin Sanchez Karver,Wendy Davis,Noya Galai,Princy Kumar,Susan Swindells,U. Fritz Bredeek,Rafael Rubio,Antonio Antela,(unknown),(unknown),Maggie Czarnogorski,Krischan J Hudson,(unknown),Deanna Kerrigan	34
4	Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) 2021 ·Patient ·Vasiliki Chounta,Edgar T. Overton,Anthony Mills,Susan Swindells,(unknown),Simon Vanveggel,Rodica Van Solingen‐Ristea,Yuanyuan Wang,Krischan J Hudson,Mark S. Shaefer,David A. Margolis,Kimberly Y. Smith,William Spreen	47
5	Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial 2020 ·AIDS Research and Human Retroviruses ·Deanna Kerrigan,Miranda Murray,Tahilin Sanchez Karver,Andrea Mantsios,(unknown),Krischan J Hudson,Emma Kaplan‐Lewis,Federico Pulido,(unknown),David M. Margolis,Noya Galai	4
6	Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials 2020 ·AIDS and Behavior ·Andrea Mantsios,Miranda Murray,Tahilin Sanchez Karver,Wendy Davis,David M. Margolis,Princy Kumar,Susan Swindells,U. Fritz Bredeek,Miguel García Deltoro,Mercedes García‐Gasalla,Rafael Rubio,Antonio Antela,Krischan J Hudson,Sandy Griffith,Deanna Kerrigan	35
7	Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks 2020 ·AIDS and Behavior ·Miranda Murray,Antonio Antela,Anthony Mills,Jenny Huang,(unknown),Enrique Bernal,Johan Lombaard,Harold Katner,Sharon Walmsley,Marie-Aude Khuong-Josses,Krischan J Hudson,David Dorey,Sandy Griffith,William Spreen,Simon Vanveggel,Mark S. Shaefer,David M. Margolis,Vasiliki Chounta	53
8	Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial 2020 ·SHILAP Revista de lepidopterología ·Miranda Murray,Deanna Kerrigan,Krischan J Hudson,Nicola Walters,Tahilin Sanchez Karver,Andrea Mantsios,Noya Galai	10
9	1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome 2020 ·Open Forum Infectious Diseases ·Christine L. Talarico,Sterling Wu,(unknown),Marty St. Clair,Veerle Van Eygen,Krischan J Hudson,Sandy Griffith,Conn Harrington,Jan van Lunzen,David M. Margolis,William Spreen	4
10	LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials 2020 ·Open Forum Infectious Diseases ·Ronald D’Amico,Paul Benn,Cynthia McCoig,Sandy Griffith,Krischan J Hudson,Kenneth Sutton,Conn Harrington,Sterling Wu,(unknown),(unknown),(unknown),(unknown),Parul Patel,David M. Margolis	2
11	2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies 2019 ·Open Forum Infectious Diseases ·Parul Patel,Susan L. Ford,Herta Crauwels,Kelong Han,Stefaan Rossenu,(unknown),Sandy Griffith,Krischan J Hudson,David M. Margolis,Mark Baker,Peter Williams,William Spreen	17
12	884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies 2019 ·Open Forum Infectious Diseases ·(unknown),Amy Cutrell,Ronald D’Amico,David Dorey,Sandy Griffith,Conn Harrington,Jenny Huang,Krischan J Hudson,David M. Margolis,Joseph Mrus,Joseph W. Polli,William Spreen,Peter Williams,Rodica Van Solingen‐Ristea,Mark S. Shaefer	4
13	Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial 2018 ·HIV Clinical Trials ·Miranda Murray,Martin Markowitz,Ian Frank,Robert M. Grant,Kenneth H. Mayer,Krischan J Hudson,Britt Stancil,Susan L. Ford,Parul Patel,Alex R. Rinehart,William Spreen,David A. Margolis	54
14	Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial 2017 ·The Lancet HIV ·Martin Markowitz,Ian Frank,Robert M. Grant,Kenneth H. Mayer,Richard Elion,Deborah Goldstein,(unknown),Magdalena E. Sobieszczyk,Joel E. Gallant,Hong‐Van Tieu,Winkler G. Weinberg,David A. Margolis,Krischan J Hudson,Britt Stancil,Susan L. Ford,Parul Patel,Elizabeth Gould,Alex R. Rinehart,Kimberly Y. Smith,William Spreen	164
15	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial 2015 ·The Lancet Infectious Diseases ·David A. Margolis,Cynthia Brinson,Graham Smith,Jerome De Vente,Debbie Hagins,Joseph J. Eron,Sandy Griffith,M H St Clair,Marita Stevens,Peter Williams,Susan L. Ford,Britt Stancil,(unknown),Krischan J Hudson,Kimberly Y. Smith,William Spreen	157
16	Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study 2015 ·British Journal of Clinical Pharmacology ·Jennifer Dong,Michelle I. Rossulek,Veena Somayaji,Daniel Baltrukonis,Yali Liang,Krischan J Hudson,Martha Hernandez‐Illas,Roberto A. Calle	85
17	Effects of a long‐acting GLP‐1 mimetic (PF‐04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus 2011 ·Diabetes Obesity and Metabolism ·Stephanie M. Gustavson,(unknown),Veena Somayaji,Krischan J Hudson,Daniel Baltrukonis,(unknown),Tracey Boyden,Roberto A. Calle	19

About Krischan J Hudson

Krischan J Hudson is a scholar working on Virology, Infectious Diseases and Toxicology, having authored 17 papers that have together received 698 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (11 papers), HIV/AIDS Research and Interventions (10 papers) and HIV Research and Treatment (9 papers). The work is most often cited by research in Virology (358 citations), Infectious Diseases (535 citations) and Emergency Medicine (84 citations). Krischan J Hudson has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include William Spreen, David A. Margolis, Susan L. Ford, Britt Stancil, Kimberly Y. Smith, Sandy Griffith, Parul Patel, Miranda Murray, Alex R. Rinehart and Martin Markowitz. Their work appears in journals such as SHILAP Revista de lepidopterología, CHEST Journal and The Lancet Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact